MX2020004495A - Composiciones y métodos para tratar la resistencia a los antibióticos. - Google Patents

Composiciones y métodos para tratar la resistencia a los antibióticos.

Info

Publication number
MX2020004495A
MX2020004495A MX2020004495A MX2020004495A MX2020004495A MX 2020004495 A MX2020004495 A MX 2020004495A MX 2020004495 A MX2020004495 A MX 2020004495A MX 2020004495 A MX2020004495 A MX 2020004495A MX 2020004495 A MX2020004495 A MX 2020004495A
Authority
MX
Mexico
Prior art keywords
compositions
methods
antibiotic resistance
treating antibiotic
treating
Prior art date
Application number
MX2020004495A
Other languages
English (en)
Inventor
Christopher Burton Ford
Jessica Bryant
Edward J O''brien
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of MX2020004495A publication Critical patent/MX2020004495A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para reducir el transporte de genes de resistencia a los antibióticos.
MX2020004495A 2017-10-30 2018-10-30 Composiciones y métodos para tratar la resistencia a los antibióticos. MX2020004495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578698P 2017-10-30 2017-10-30
US201862741346P 2018-10-04 2018-10-04
PCT/US2018/058279 WO2019089643A1 (en) 2017-10-30 2018-10-30 Compositions and methods for treating antibiotic resistance

Publications (1)

Publication Number Publication Date
MX2020004495A true MX2020004495A (es) 2021-01-08

Family

ID=64607291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004495A MX2020004495A (es) 2017-10-30 2018-10-30 Composiciones y métodos para tratar la resistencia a los antibióticos.

Country Status (11)

Country Link
US (1) US20200353018A1 (es)
EP (1) EP3703720A1 (es)
JP (1) JP2021501185A (es)
KR (1) KR20200079292A (es)
CN (1) CN111432826A (es)
AU (1) AU2018360561A1 (es)
BR (1) BR112020008552A2 (es)
CA (1) CA3080586A1 (es)
MX (1) MX2020004495A (es)
RU (1) RU2020117775A (es)
WO (1) WO2019089643A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2951285A4 (en) 2013-02-04 2016-10-26 Seres Therapeutics Inc COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF PATHOGENIC BACTERIA
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2017249159A1 (en) 2016-04-11 2018-11-29 President And Fellows Of Harvard College Probiotic formulations for improving athletic performance
RU2020110462A (ru) 2017-08-14 2021-09-16 Серес Терапеутикс, Инк. Композиции и способы для лечения холестатического заболевания
CA3101184A1 (en) * 2018-05-24 2019-11-28 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
EP4066844A1 (en) * 2019-07-05 2022-10-05 4D Pharma Research Limited Compositions comprising anaerostipes hadrus
BR112022010174A2 (pt) * 2019-11-25 2022-08-09 Fitbiomics Inc Composições para aperfeiçoamento do desempenho atlético e métodos de uso das mesmas
CN111157722B (zh) * 2019-11-25 2022-10-11 广州惠善医疗技术有限公司 生物标志物的用途
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
WO2021252860A2 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using harryflintia acetispora
WO2022035269A1 (ko) * 2020-08-14 2022-02-17 주식회사 고바이오랩 피칼리박테리움 프라우스니치이 균주 및 그 용도
CN116473222A (zh) * 2022-01-17 2023-07-25 中国科学院上海营养与健康研究所 调控脂质吸收的方法、组合物及其应用
CN114807348B (zh) * 2022-04-21 2024-05-07 济南大学 长链非编码rna lra-1及其干扰rna在治疗动脉粥样硬化中的应用
CN116042432A (zh) * 2022-07-14 2023-05-02 沈阳医学院 一种具有广谱抑菌性的新菌种及其抑菌物质的提纯

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) * 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2951285A4 (en) * 2013-02-04 2016-10-26 Seres Therapeutics Inc COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF PATHOGENIC BACTERIA
WO2014153194A2 (en) * 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
EP2967077A4 (en) * 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
AU2014352643A1 (en) * 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2015264266A1 (en) * 2014-05-19 2016-12-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing Clostridium difficile infection
BR112018000204A2 (pt) * 2015-07-08 2018-09-04 Seres Therapeutics Inc métodos de tratamento de colite
FI3380108T3 (fi) * 2015-11-24 2023-03-03 Seres Therapeutics Inc Suunniteltuja bakteerikoostumuksia
AU2016361583B2 (en) * 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Also Published As

Publication number Publication date
AU2018360561A1 (en) 2020-05-21
RU2020117775A (ru) 2021-12-01
EP3703720A1 (en) 2020-09-09
CA3080586A1 (en) 2019-05-09
KR20200079292A (ko) 2020-07-02
CN111432826A (zh) 2020-07-17
JP2021501185A (ja) 2021-01-14
US20200353018A1 (en) 2020-11-12
WO2019089643A1 (en) 2019-05-09
BR112020008552A2 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
MX2020004495A (es) Composiciones y métodos para tratar la resistencia a los antibióticos.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
CL2017003404A1 (es) Compuestos antibacterianos
CR20180058A (es) Nuevos derivados de fenoximetilo
CO2017013709A2 (es) Lactamas bicíclicas.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
SV2018005662A (es) Moduladores del receptor x farnesoide
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MA52546A (fr) Compositions ciblées
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
UY37487A (es) Amidas heterocíclicas como inhibidores de quinasa
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
UY36204A (es) Derivados de insoindolina.
CL2016002700A1 (es) Composiciones de siloxano y métodos para reducir los cov y el polvo de siloxano
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017022281A2 (pt) métodos para tratar câncer
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t